Somebody asked me about the way forward and a few

Quote:

---

I think the only way any BP is affecting enrollment is because they are also running trials there and competing for patients. But in a highly corrupt country like Brazil never count anything out.

I've voted against the comp plan at every shareholders meeting since I've bought shares. If they want a lot of shares they should show us approvals. I can understand why they'd want to frontload. Better to have a $1.36 option exercise price then a $20 one. But if Nader grabs those 4 million shares now and then comes back after approval for a large amount on approval I'll vote against him myself.

The 13d are stupid as hell to think either management or shareholders would fall for that $100 million in financing offer. What that offer would consist of is their pipe dream that the two financing companies that Cytodyn talked to would step in. But that would involve using IP as collateral so we'd never agree to that.

So the 13d are going to offer us a deal Cytodyn already turned down and then give us 10% of the revenue in longhaulers which would be only enough to cover our royalties which means we'd get no U.S. revenue for longhaulers. They're proposing stuff out of desperation because IncellDX is a money losing company.

The only red flags I see are the 50 patient interim analysis but I'm sure the number of patients will be increased for the interim or they'll do two interims and time but that's not really a red flag it's just a matter of patience. The 13d not sending their proxies and the delay due to the court of Cytodyn sending out their proxies cost us another month. Which is why the severe Covid trial is being slowed down and longhaulers won't launch until January.

The BLA for HIV I really don't care about. It's very small revenue compared to other indications and we should just start the monotherapy trial instead.

What steels my resolve is that I have done a ridiculous amount of due diligence on the medical side and have a pretty good idea of the broad number of indications it will work in. Enough to challenge some of the doctors (including Patterson) and so called medical experts (like JLang refuting my saying there's a small possibility leronlimab would work for MS but it would never work for ALS, but long after that Dr. Recknor said Cytodyn would be looking at MS and ALS). The only thing needed is cash and even if a quorum is not present Nov. 28th we can go to the Delaware Chancery Court and have them declare a quorum even with too few proxies.

What's nearly certain to give us revenue is the critical Covid trial. If they want to try for EUA at interim then ditch the idea of only using 50 patients. But with IV and the primary endpoint we have, if nothing else the full trial results will give us an excellent p value.

---